Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT ...

Inhibikase Therapeutics is meanwhile running early-stage trials of a c-Abl inhibitor and Denali Therapeutics/Biogen are working on an LRRK2 inhibitor in Parkinson's, both hoping to show that the ...

At close: June 4 at 4:00:01 PM EDT ...

Inhibikase Therapeutics, Inc. (IKT) earnings estimates: forecast for revenue and EPS, high & low, YoY growth, forward PE and number of analysts. Skip to content Home page Seeking Alpha - Power to ...

Turbocharge the Development of the Best-In-Class Kinase Inhibitor Products, to Enhance Specificity, Overcome Resistance to Deliver Safe & Durable Clinical Responses Celebrating 20 years of FDA ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.